NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of BioMed Realty Trust, Inc. (NYSE: BMR) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop BioMed Realty Trust to maximize shareholder value before agreeing to be acquired by Blackstone Real Estate Partners VIII.
If you would like to join the action, go to the firm’s website at http://rosenlegal.com/cases-742.html or contact Phillip Kim or Kevin Chan toll-free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.
Under the terms of the proposed transaction, shareholders will receive $23.75 in cash for each share of BioMed Realty Trust common stock they own. The proposed transaction is valued at approximately $8 billion. The investigation relates to whether the proposal is fair to the public shareholders of BioMed Realty Trust and whether BioMed Realty Trust’s Board breached its fiduciary duties in connection with the proposed sale.
If you currently own shares of BioMed Realty Trust and wish to obtain additional information, please visit the firm’s website at http://rosenlegal.com/cases-742.html. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
